Aidoc

What is Aidoc and who sells it?

Aidoc describes itself as a "pioneering force in clinical AI" aimed at helping healthcare teams treat patients faster (Aidoc About page, October 2026). The product has two layers. The first is a set of algorithms, marketed under names such as BriefCase, for triage and notification in radiology, quantification, cardiology and neurovascular findings such as stroke, hemorrhage, c-spine fracture and aneurysm. The second is aiOS, which the company calls a platform to "run, orchestrate and govern" clinical AI across a health system, with validation, drift detection, override tracking and analytics. The home page claims its solutions cover 75% of patients in a health system, which is the vendor's figure.

The company is Aidoc Medical Ltd., established in 2016 by four founders from the Israeli Defense Forces Talpiot program, according to its About page. Wikipedia names Elad Walach as CEO and Michael Braginsky as CTO, with headquarters in Tel Aviv and a US presence in New York. It is venture-backed. A $150M growth round in July 2025 was led by General Catalyst and Square Peg. A $150M Series E followed on April 29, 2026, led by Growth Equity at Goldman Sachs Alternatives with General Catalyst, SoftBank Vision Fund 2 and NVentures, taking total funding to "over $500 million" in the company's words. Tracxn puts the total at $534M.

Where is Aidoc strong?

Aidoc's strength is breadth. One vendor covers a set of radiology, neurovascular and cardiology modules, and aiOS puts them on one orchestration layer (Aidoc platform page). A department that would otherwise buy several single-purpose tools and manage several sets of alerts has a reason to look.

Aidoc also publishes its quality systems. Its quality page lists ISO 13485:2016, MDSAP and EU MDR 2017/745 certification, with compliance to 21 CFR 820, ISO 14971 and IEC 62304, updated July 2025. It states the limit of its own product: triage tools "are not diagnostic software and are not intended to replace a clinician's full interpretation" (Aidoc quality and compliance page).

What do the FDA record and the compliance pages show?

The FDA database lists 35 510(k) records for the applicant "Aidoc Medical , Ltd.", queried in October 2026, all marked substantially equivalent. The product codes are QAS and QFM, which cover radiological computer-assisted triage and notification, and QIH and JAK, which cover image analysis and quantification. The first record, K180647 (BriefCase), is from August 2018, and 2022 was the busiest year with 10 records. Indications are listed per K-number on the FDA 510(k) page.

Aidoc's own pages give different numbers. The About page says "Most FDA-clearances in clinical AI (17)" and more than 1,600 medical centers. The April 2026 Series E release says "nearly 2,000 hospitals".

Aidoc says its CARE foundation model, the Clinical AI Reasoning Engine, was FDA-cleared in early 2026 as CT triage for 11 indications. The database lists two 2026 CARE records, K252970 in January and K253578 in February. Aidoc also received Breakthrough Device Designation in September 2025, per Wikipedia, which is a designation and not a clearance.

Aidoc's pages do not state HIPAA, SOC 2 or HITRUST status. The platform page says aiOS integrates with PACS, EHR, mobile and care tools without naming systems.

What does the independent evidence say?

The independent study to read is a real-world evaluation of BriefCase intracranial hemorrhage triage in npj Digital Medicine (2025, PMID 41444826), run in an academic system across 17 facilities and 101,944 head CTs. Sensitivity was 82.2%, specificity 97.6% and accuracy 96.6%. Sensitivity fell to 45.5% for subacute bleeds and 54.8% for chronic ones, and to 74.8% for bleeds of 10 mm or less. A triage tool that rarely raises a false alarm but misses roughly one in five bleeds, and more among the small and old ones, works only where a radiologist still reads every study.

How does Aidoc compare with Viz.ai and RapidAI?

Web comparisons pair Aidoc with Viz.ai and RapidAI. The wider radiology set is Annalise.ai, Rad AI, Qure.ai, MaxQ (Accipio) and Lunit. Aidoc starts from radiology worklists and extends into a platform, which points to the radiology department or imaging service line as buyer. A hospital that wants a diagnostic read from software should not buy any of them.

How much does Aidoc cost?

Aidoc publishes no price on its own site. The one concrete list price is on AWS Marketplace, where the "Clinical AI Starter" is listed at $6.00 per scan per Aidoc AI algorithm for each hospital site, on a 12-month contract, by private offer only, with no trial stated (AWS Marketplace listing, October 2026). Full enterprise contracts are quoted.

Medicare adds a payment route for one product. MarketScale reports that CMS set a maximum add-on payment of $137.53 per eligible inpatient case for BriefCase-Triage CT Body, billable from October 1, 2026 (fiscal year 2027).

Who is Aidoc for?

A health system radiology chair who wants triage across head, chest and body CT under one contract and one governance console is the intended buyer. An imaging service line weighing the Medicare add-on payment for CT body triage has a concrete number to build on. A neuroradiologist at a small community hospital who is worried about missed small bleeds should read the npj Digital Medicine numbers before assuming the tool closes the gap.

The verdict

Buy Aidoc as a prioritization layer in a health system that already reads every CT with a radiologist and wants many triage findings under one vendor. Pass if you hope to reduce missed small or chronic bleeds, since the best independent data show the weakest sensitivity there. A single-condition program is better off pricing a narrower tool.